Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Tripstar: a comprehensive patient-based approach to compare triptans.

Tripstar: a comprehensive patient-based approach to compare triptans. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Tripstar: a comprehensive patient-based approach to compare triptans. Abstract Text:

    michel d ferrariMichel D Ferrari,

    Several second-generation triptans have been introduced that differ in their pharmacologic profiles relative to each other and to sumatriptan. As therapeutic options multiply, clinicians must be able to distinguish among these compounds. Recently, a meta-analysis was conducted on data from 53 double-blind, randomized, placebo- or active-controlled trials involving over 24 000 patients receiving oral triptans. Results indicated that almotriptan 12.5 mg, rizatriptan 10 mg, and eletriptan 80 mg are generally superior to sumatriptan 100 mg based on individual treatment attributes, such as pain relief, sustained pain freedom, consistency of response, and tolerability. Meta-analyses are limited, however, as the analysis can only be performed for individual end points, whereas patients and prescribers balance a variety of treatment attributes when assessing drug acceptability. A flexible overall scoring system ("Tripstar") is proposed that compares triptans to a hypothetical "ideal" using meta-analysis data combined with ratings of the relative importance of clinically relevant treatment criteria. An informal test of the Tripstar model indicated that sumatriptan is most similar to a hypothetical ideal for both mild and severe migraine, primarily due to its high worldwide clinical exposure. However, after exclusion of worldwide exposure as a contributing factor, almotriptan 12.5 mg is most similar to the ideal, principally because of its good tolerability. Further tests of the Tripstar model are planned that will gauge the relative importance of a broader range of attributes.

    Tripstar: a comprehensive patient-based approach to compare triptans. Publishing Authors By Initials

    md ferrariMD Ferrari,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Tripstar: a comprehensive patient-based approach to compare triptans. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Headache

    VOLUME: 42 Suppl 1

    Page Numbers: 18-25

    Journal Abbreviation:

    ISSN: 0017-8748

    DAY: 22

    MONTH: Jan

    YEAR: 2002

    Tripstar: a comprehensive patient-based approach to compare triptans. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 2985091

    Tripstar: a comprehensive patient-based approach to compare triptans. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Tripstar: a comprehensive patient-based approach to compare triptans. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Tripstar: a comprehensive patient-based approach to compare triptans.

    AFFILIATION: Department of Neurology, Leiden University Medical Centre, The Netherlands.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Headache

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Tripstar: a comprehensive patient-based approach to compare triptans Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News